Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Jul 14;339:b2576.
doi: 10.1136/bmj.b2576.

Laparoscopic Fundoplication Compared With Medical Management for Gastro-Oesophageal Reflux Disease: Cost Effectiveness Study

Collaborators, Affiliations
Free PMC article
Randomized Controlled Trial

Laparoscopic Fundoplication Compared With Medical Management for Gastro-Oesophageal Reflux Disease: Cost Effectiveness Study

David Epstein et al. BMJ. .
Free PMC article

Abstract

Objective: To describe the long term costs, health benefits, and cost effectiveness of laparoscopic surgery compared with those of continued medical management for patients with gastro-oesophageal reflux disease (GORD).

Design: We estimated resource use and costs for the first year on the basis of data from the REFLUX trial. A Markov model was used to extrapolate cost and health benefit over a lifetime using data collected in the REFLUX trial and other sources.

Participants: The model compared laparoscopic surgery and continued proton pump inhibitors in male patients aged 45 and stable on GORD medication.

Intervention: Laparoscopic surgery versus continued medical management.

Main outcome measures: We estimated quality adjusted life years and GORD related costs to the health service over a lifetime. Sensitivity analyses considered other plausible scenarios, in particular size and duration of treatment effect and the GORD symptoms of patients in whom surgery is unsuccessful. Main results The base case model indicated that surgery is likely to be considered cost effective on average with an incremental cost effectiveness ratio of pound2648 (euro3110; US$4385) per quality adjusted life year and that the probability that surgery is cost effective is 0.94 at a threshold incremental cost effectiveness ratio of pound20 000. The results were sensitive to some assumptions within the extrapolation modelling.

Conclusion: Surgery seems to be more cost effective on average than medical management in many of the scenarios examined in this study. Surgery might not be cost effective if the treatment effect does not persist over the long term, if patients who return to medical management have poor health related quality of life, or if proton pump inhibitors were cheaper. Further follow-up of patients from the REFLUX trial may be valuable.

Trial registration: ISRCTN15517081.

Conflict of interest statement

Competing interests: None declared.

Figures

None
Fig 1 Model structure

Comment in

Similar articles

See all similar articles

Cited by 17 articles

See all "Cited by" articles

References

    1. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000;14:1589-94. - PubMed
    1. van Pinxteren B, Numans MME, Bonis P, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Reviews 2006;3:CD002095. - PubMed
    1. McDougall NI, Johnston BT, Kee F, Collins J, McFarland R, Love AH. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996;38:481-6. - PMC - PubMed
    1. Norris L. Update on growth in prescription volume and cost in the year to December 2007. London: NHS Business Services Authority, 2008:1-13. www.nhsbsa.nhs.uk.
    1. Arguedas MR, Heudebert GR, Klapow JC, Centor RM, Eloubeidi MA, Wilcox CM, et al. Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection. Am J Gastroenterol 2004;99:1023-8. - PubMed

Publication types

MeSH terms

Substances

Associated data

Feedback